| Entries |
| Document | Title | Date |
|---|
| 20090176817 | Method of Treatment of Diarrhea-Predominant Irritable Bowel Syndrome in a Subject - A method of improving stool frequency in a subject having diarrhea-predominant IBS, comprising administering a composition comprising cilansetron or a pharmaceutically acceptable derivative thereof to a subject in need of treatment in an amount sufficient to decrease stool frequency within 2 days or less of administering. | 07-09-2009 |
| 20100076010 | ALPHA 1A-ADRENOCEPTOR ANTAGONISTS - This invention relates to novel compounds that are dihydroindoles derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel dihydroindoles derivatives that are derivatives of silodosin. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an α-1A-adrenoreceptor antagonist, such as silodosin. | 03-25-2010 |
| 20100041690 | Co-Administration of Dopamine-Receptor Binding Compounds - Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D | 02-18-2010 |
| 20090318488 | Pharmaceutically acceprable salts of aporphine compounds of carboxyl group-containing agents and methods for preparing the same - The present invention discloses novel pharmaceutically acceptable salts of aporphine compounds and carboxyl-group containing agents. Also, the present invention discloses methods for preparing the pharmaceutically acceptable salts. These pharmaceutically acceptable salts are suitable for use in treating and/or preventing hyperglycemic disease and/or several oxidative stress related diseases. | 12-24-2009 |
| 20090048283 | Salt of an androgen receptor modulator - The biphthalate salts of compound I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents. | 02-19-2009 |
| 20090069364 | PHARMACEUTICAL COMPOSITIONS OF 5-ALPHA-REDUCTASE INHIBITORS AND METHODS OF USE THEREOF - Non-occlusive compositions for transdermal delivery of 5-alpha-reductase inhibitors, and more particularly finasteride or dutasteride or pharmaceutically acceptable salts or derivatives thereof, and methods of making same. The composition may, for example, be a gel suitable for transdermal or transmucosal applications. The compositions of the present invention typically include a mixture of water and alcohol, and a solvent system having a mono alkyl ether of diethylene glycol and a glycol present in specified ratios and in specific amounts, wherein the pH of the gel is usually between about pH 4.5 and about pH 8. The compositions may include further components, for example, the hydroalcoholic vehicle may further include additional penetration enhancer(s), buffering agent(s), antioxidant(s), stabilizer(s) and/or gelling agent(s). Also, a method for the sustained delivery of 5-alpha-reductase inhibitors to treat a variety of conditions and disorders. | 03-12-2009 |
| 20090023766 | Pharmaceutical formulation of apomorphine for buccal administration - The present invention provides a kit comprising, in separate compartments of a container, the following components (a) and (b): (a) a combination of apomorphine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable excipient or carrier; and (b) a solution which comprises a diluent and a pH modifying agent; the components being presented such that they can be combined at the point of use into a formulation which is adjusted to a pH ranging from mildly acidic to alkaline and which is suitable for buccal administration. The formulation is useful in treating Parkinson's disease and in promoting sexual function. | 01-22-2009 |
| 20090149488 | Tetrahydroprotoberberine Compounds, the Synthetic Method and the Use Thereof - The present invention relates to tetrahydroprotoberberines of the formula (I) and the physiologically acceptable salts thereof. The invention also relates to the use of the compounds of the formula (I) or pharmaceutically acceptable salts thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with dopamine receptor ligand, such as schizophrenia. | 06-11-2009 |
| 20090012112 | Alpha 1A-adrenoceptor antagonists - This invention relates to novel compounds that are dihydroindoles derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel dihydroindoles derivatives that are derivatives of silodosin. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an α- | 01-08-2009 |
| 20080312266 | Steroidal Compounds For Inhibiting Steroid Sulphatase - There is provided a compound having Formula (I) wherein G is H or a substituent, and wherein R | 12-18-2008 |
| 20100120817 | AZONAFIDE DERIVED TUMOR AND CANCER TARGETING COMPOUNDS - An azonafide-based compound of Formula I, a composition comprising the compound, and a method of using the compound to deliver a cytotoxic azonafide derivative to a cell, as well as related compounds and methods for the use thereof to pre-pare an azonafide-based compound of Formula I. | 05-13-2010 |
| 20110172261 | DIBENZO[f,h]ISOQUINOLINE DERIVATIVES - A group of novel dibenzo[f,h]isoquinoline derivatives as shown in the specification. Also disclosed are methods of using the compounds for treating a disease associated with NO overproduction, cancer, or viral infection. | 07-14-2011 |
| 20090163529 | IDENTIFYING THERAPEUTIC COMPOUNDS BASED ON THEIR PHYSICAL-CHEMICAL PROPERTIES - The present invention is directed to rapid and efficient methods of identifying therapeutic compounds by allowing only the most favorable molecules initially selected based on their physical-chemical profile falling within a range predefined by the physical-chemical/biological relationship of a previously tested small subset of compounds of same core structure to be assayed; and to the therapeutic compositions identified by said methods. | 06-25-2009 |
| 20090182000 | STEROIDAL COMPOUNDS AS STEROID SULPHATASE INHIBITORS - There is provided a compound having Formula I | 07-16-2009 |
| 20090143418 | Compositions and Methods for Preventing and Treating Hair Growth Cycle-Related Conditions - The present invention relates to compositions and methods for the preventing, treating, and researching discoloration (e.g., hair graying, hair whitening, undesired change in hair color). In particular, the present invention provides compositions and methods for treating, preventing and researching hair discoloration through inhibition of mTOR function (e.g., mTOR activity, mTOR expression). In addition, the present invention provides methods and compositions that utilize mTOR inhibiting agents in the preventing, treating, and researching hair discoloration. | 06-04-2009 |
| 20100004277 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING - Disclosed are compositions and methods for modulating protein trafficking and treating or preventing disorders characterized by impaired protein trafficking. Also disclosed are methods for identification of compounds that rescue protein trafficking defects and methods of enhancing protein production. | 01-07-2010 |
| 20110230513 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSONS DISEASE - Pharmaceutical compositions are provided for treatment of Parkinson's disease comprising a pharmaceutically acceptable carrier and a fixed dose combination of two active agents selected from compounds having either neuroprotective or symptomatic effects, or both, in Parkinson's disease patients, wherein the molar ratio of the two compounds is in the range of 1:1 to 1:100. The compositions are formulated for immediate release, controlled release, or both immediate and controlled release | 09-22-2011 |
| 20090318489 | Aporphine compounds and pharmaceutical use thereof - The present invention discloses novel aporphine derivatives. Also, the present invention discloses that these novel aporphine derivatives can be used for treating oxidative stress induced diseases such as cardiovascular disease, diabetes, aging, Alzheimer's disease, kidney disease, cancer or brain ischemic disease etc. | 12-24-2009 |
| 20090076058 | DEUTERIUM-ENRICHED FINASTERIDE - The present application describes deuterium-enriched finasteride, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
| 20110015222 | Benzoquinolizinium salt derivatives as anticancer agents - 13-substituted 5,6-dihydrodibenzo[a,g]quinolizinium salt compounds of the general formula (I): | 01-20-2011 |
| 20080318995 | N-Substituted Indenoisoquinolines and Syntheses Thereof - N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof. | 12-25-2008 |
| 20120302593 | Use of at Least One Isoquinoline Compound of Formula I, Pharmaceutical Composition for Treating or Preventing Neurodegenerative Diseases and Method for Treating or Preventing Neurodegenerative Diseases - The present invention concern the use of isoquinoline alkaloid compounds of formula I in the preparation of pharmaceutical compositions useful in the treatment of neurodegenerative diseases, particularly Alzheimer's disease, as well as pharmaceutical composition comprising said compounds and method of treatment of neurodegenerative diseases | 11-29-2012 |
| 20100311785 | Combination Therapy For Modulating The Human Sexual Response - The invention is directed to compositions and methods for modulating the human sexual response. The compositions comprise two or more pharmaceutically active agents which preferably include an alpha-adrenergic antagonist and a phosphodiesterase inhibitor. | 12-09-2010 |
| 20100324079 | Medicament for prophylaxis and treatment of Alzheimer disease - A medicament effective for inhibiting onset of Alzheimer disease via intracellular aggregation mechanism is provided. A medicament for prophylaxis and treatment of Alzheimer disease comprising as an active ingredient apomorphine hydrochloride wherein cell death dependent upon intracellularly accumulated amyloid β proteins and/or p53 is inhibited; and/or wherein a level of intracellularly accumulated amyloid β proteins and/or phosphorylated tau proteins is lowered to improve energy production, protein metabolism and synaptic function of neurons so as to ameliorate the recognition capacity such as defects of memory. A medicament for prophylaxis and treatment of Alzheimer disease according to the present invention may allow for eradicative treatment of Alzheimer disease due to its inhibition of intracellular coagulation and accumulation of amyloid β proteins and intracellular activation of proteasome, and even prior to occurrence of massive neuronal death, may improve the function per se of neurons by reducing intracellularly accumulated amyloid β proteins to thereby contribute amelioration of the recognition function of Alzheimer disease patients. | 12-23-2010 |
| 20110086875 | Powdered Medicament for Nasal Delivery of Ascorbic Acid for Reducing Apomorphine Induced Toxicity to Ciliated Tissue - Use of ascorbic acid in the manufacture of a powdered medicament for nasal delivery, said medicament comprising an active agent such as apomorphine that exhibits toxicity to ciliated tissue, for ameliorating said toxicity. | 04-14-2011 |
| 20110190332 | DOPAMINE RECEPTOR LIGANDS WITH ENHANCED DURATION OF ACTION - Trans-hexahydrobenzoaphenanthridines of the formula (I) wherein X, Y, R | 08-04-2011 |
| 20100249170 | INTRANASAL COMPOSITIONS - A liquid aqueous formulation for the intranasal administration of apomorphine includes:
| 09-30-2010 |
| 20090270439 | Prophylactic/therapeutic agent for alzheimer's disease - A medicament effective for inhibiting onset of Alzheimer disease via intracellular aggregation mechanism is provided. A medicament for prophylaxis and treatment of Alzheimer disease comprising as an active ingredient apomorphine hydrochloride wherein cell death dependent upon intracellularly accumulated amyloid β proteins and/or p53 is inhibited; and/or wherein a level of intracellularly accumulated amyloid β proteins and/or phosphorylated tau proteins is lowered to improve energy production, protein metabolism and synaptic function of neurons so as to ameliorate the recognition capacity such as defects of memory. A medicament for prophylaxis and treatment of Alzheimer disease according to the present invention may allow for eradicative treatment of Alzheimer disease due to its inhibition of intracellular coagulation and accumulation of amyloid β proteins and intracellular activation of proteasome, and even prior to occurrence of massive neuronal death, may improve the function per se of neurons by reducing intracellularly accumulated amyloid β proteins to thereby contribute amelioration of the recognition function of Alzheimer disease patients. | 10-29-2009 |
| 20090239894 | Stabilized aqueous solutions of ergoline compounds - The present invention relates to stabilized aqueous solutions of an ergoline compound of formula I | 09-24-2009 |
| 20090203724 | SOLID AND CRYSTALLINE DUTASTERIDE AND PROCESSES FOR PREPARATION THEREOF - The solid state chemistry of 17β-N-[2,5-bis(trifluoromethyl)phenyl]carbamoyl-4-aza-5-α-androst-1-en-3-one of which the international nonproprietary name is Dutasteride (the active ingredient in products marketed as Avodart, Avidart, Avolve, Duagen, Dutas, Dutagen, Duprost) and its process for preparing. The synthetic process comprises formation of the mixed anhydride, its subsequent reaction with 2,5-bis(trifluoromethyl)phenylamine in the presence of an appropriate Lewis catalyst and its isolation, purification and crystallization from acetonitrile/water. | 08-13-2009 |
| 20090170889 | USE OF FINASTERIDE, DUTASTERIDE AND RELATED COMPOUNDS FOR THE PREVENTION OR TREATMENT OF NEUROLOGICALLY-ASSOCIATED DISORDERS - The present invention relates to new pharmaceutical uses of 4-azasteroid compounds, in particular of Finasteride/Dutasteride/Dutasteride and Dutasteride, particularly preferred of Finasteride/Dutasteride/Dutasteride, and its pharmaceutically acceptable derivatives, and combinations comprising said compounds. The invention also features generally the use of a modulator compound of neuroprotective conditions via beta subunits of shaker-type voltage-gated potassium channels and/or via members of solute carriers family 25, in particular Aralar (member 12) and adenine-nucleotide translocators 1 & 2 (member 4 & 5) and/or via a 4-nitrophenylphosphatase domain and non-neuronal SNAP25-like protein homolog 1 (NIPSNAP 1) as a neuroprotective medicament, particularly as a medicament for the prevention and/or treatment of neurological diseases such as dementia, Parkinson, Alzheimer, schizophrenia or epilepsy. The demonstrated inhibition of the MPTP appears to constitute a novel principle applicable to all pathological conditions which have underlying excitotoxic/mitochondrial mechanisms, like: amyotrophic lateral sclerosis, Alzheimer's disease, depression, epilepsy, multiple sclerosis, pain, Parkinson's disease, schizophrenia, traumatic brain and spinal chord injury, stroke and other ischemic conditions in the brain. | 07-02-2009 |
| 20120041015 | METHOD AND COMPOSITION FOR TREATING NODULOCYSTIC AND CONGLOBATE ACNE VULGARIS - Methods and compositions are described for the treatment of very severe acne vulgaris, including nodulocystic acne and conglobate acne. Compounds which inhibit either or both type 1 and type 2 isoforms of steroid 5α-reductase are administered daily in either oral or topical formulations to patients suffering from severe forms of acne vulgaris. Very high dosages of such compounds can effectively be administered oral just once a week and be successful. | 02-16-2012 |
| 20080214593 | TETRACYCLIC AMINO AND CARBOXAMIDO COMPOUNDS AND METHODS OF USE THEREOF - The present invention relates to Tetracyclic Amino Compounds and Tetracyclic Carboxamido Compounds, compositions comprising an effective amount of a Tetracyclic Amino Compound or a Tetracyclic Carboxamido Compound and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, Parkinson's disease, renal failure, a vascular disease, a cardiovascular disease, or cancer, comprising administering to a subject in need thereof an effective amount of a Tetracyclic Amino Compound or a Tetracyclic Carboxamido Compound. | 09-04-2008 |
| 20120041016 | 11-Aza, 11-Thia and 11-Oxa Sterol Compounds and Compositions - The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations. | 02-16-2012 |
| 20090076057 | DEUTERIUM-ENRICHED DUTASTERIDE - The present application describes deuterium-enriched dutasteride, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
| 20120059026 | ANTIMICROBIAL AGENTS - The invention provides a compound of formula (I): or a salt or prodrug thereof, wherein Y, W, Z, Z | 03-08-2012 |
| 20110092533 | COMPOUNDS FOR BINDING TO ER ALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF - The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ERα and ERβ). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors. Diseases which are mediated through one or more of these receptors include cancer (particularly breast, reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometreitis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disoders such as Parkinson's disease and Alzheimer's disease, as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention. | 04-21-2011 |
| 20110092532 | APOMORPHINE PHARMACEUTICAL DOSAGE SECURITY SYSTEM - An apomorphine pharmaceutical dosage security system embodied in multiple dosage forms including oral dosage forms, transdermal delivery patches, nasal delivery forms, and transdermal dosage forms. Within the present invention is an amount of apomorphine adapted to be bioavailable to a degree sufficient to cause emesis or severe nausea when an overdose amount of a therapeutic agent enters systemic circulation. | 04-21-2011 |
| 20120101119 | N-substituted indenoisoquinolines and syntheses thereof - N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof. | 04-26-2012 |
| 20080242692 | Synthesis of Indenoisoquinoliniums and Methods of Use - Substituted indenoisoquinolinium compounds, and pharmaceutical formulations of substituted indenoisoquinolinium compounds are described. Also described are processes for preparing substituted indenoisoquinolinium compounds. Also described are methods for treating cancer in mammals using the described substituted indenoisoquinolinium compounds or pharmaceutical formulations thereof. | 10-02-2008 |
| 20130131098 | PHARMACEUTICAL FORMULATION OF APOMORPHINE FOR BUCCAL ADMINISTRATION - The present invention provides a kit comprising, in separate compartments of a container, the following components (a) and (b): (a) a combination of apomorphine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable excipient or carrier; and (b) a solution which comprises a diluent and a pH modifying agent; the components being presented such that they can be combined at the point of use into a formulation which is adjusted to a pH ranging from mildly acidic to alkaline and which is suitable for buccal administration. The formulation is useful in treating Parkinson's disease and in promoting sexual function. | 05-23-2013 |
